Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H22O10 |
Molecular Weight | 482.4362 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC=C1O)[C@H]2OC3=CC(=CC=C3O[C@@H]2CO)[C@H]4OC5=C(C(=O)[C@@H]4O)C(O)=CC(O)=C5
InChI
InChIKey=SEBFKMXJBCUCAI-HKTJVKLFSA-N
InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
Molecular Formula | C25H22O10 |
Molecular Weight | 482.4362 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/17305535 | http://www.webmd.com/heart-disease/milk-thistle-benefits-and-side-effects#1
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/17305535 | http://www.webmd.com/heart-disease/milk-thistle-benefits-and-side-effects#1
Silymarin, a plant-derived flavonoid from the plant Silybum marianum, is considered the most potential drug to treat almost all kind of liver diseases, particularly alcoholic liver disease, acute and chronic viral hepatitis and toxins-mediated liver dysfunctions. The main component of the silymarin complex is silybin, synonymous with silibinin, sometimes incorrectly called silybinin, which is a mixture of two diastereomers A and B in approximately 1:1 proportion. The drug possess hepatoprotective and antioxidant activity. The hepatoprotective effect is due to stimulation of synthesis of structural and functional proteins and phospholipids, as well as acceleration of the regeneration of hepatocytes. Antioxidant effect is determined by interaction of bioflavones with free radicals in the liver and its detoxication. In such manner the process of peroxidation of the lipids is interrupted and further liver destruction is prevented. Side effect is a mild laxative effect has occasionally been observed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006979 |
|||
Target ID: CHEMBL3021 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14568570 |
|||
Target ID: CHEMBL4302 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Milk Thistle Approved UseIt is indicated for the treatment of jaundice, chronic inflammatory liver conditions, i.e. hepatitis, alcoholic liver damage and hepatic cirrhosis. Launch Date9.7666558E11 |
|||
Primary | Milk Thistle Approved UseIt is indicated for the treatment of jaundice, chronic inflammatory liver conditions, i.e. hepatitis, alcoholic liver damage and hepatic cirrhosis. Launch Date9.7666558E11 |
|||
Primary | Milk Thistle Approved UseIt is indicated for the treatment of jaundice, chronic inflammatory liver conditions, i.e. hepatitis, alcoholic liver damage and hepatic cirrhosis. Launch Date9.6880322E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of reverse transcriptases by flavonoids. | 1989 Sep |
|
Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. | 1999 Sep |
|
Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. | 2005 Nov |
|
Antiparasitic activity of flavonoids and isoflavones against Cryptosporidium parvum and Encephalitozoon intestinalis. | 2006 Jun |
|
Effect of silibinin on the growth and progression of primary lung tumors in mice. | 2006 Jun 21 |
|
MDR- and CYP3A4-mediated drug-herbal interactions. | 2006 Mar 27 |
|
Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. | 2006 Nov |
|
Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines. | 2007 Feb |
|
Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells. | 2007 Nov |
|
Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice. | 2007 Oct |
|
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. | 2009 Mar 16 |
|
The protective effect of silibinin against mitomycin C-induced intrinsic apoptosis in human melanoma A375-S2 cells. | 2009 Oct |
|
Multiple effects of silymarin on the hepatitis C virus lifecycle. | 2010 Jun |
|
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. | 2010 Mar |
|
Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation. | 2010 Mar |
|
Identification of hepatoprotective flavonolignans from silymarin. | 2010 Mar 30 |
|
Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. | 2011 Jan 28 |
|
Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model. | 2012 Aug |
|
Silibinin ameliorates arsenic induced nephrotoxicity by abrogation of oxidative stress, inflammation and apoptosis in rats. | 2012 Dec |
|
Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. | 2012 Feb |
|
Metabolic effects of silibinin in the rat liver. | 2012 Jan 25 |
|
In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds. | 2012 Jul |
|
Antiplasmodial activity of flavonol quercetin and its analogues in Plasmodium falciparum: evidence from clinical isolates in Bangladesh and standardized parasite clones. | 2012 Jun |
|
Silibinin potentially protects arsenic-induced oxidative hepatic dysfunction in rats. | 2012 May |
|
Silibinin as a potential therapeutic for sulfur mustard injuries. | 2013 Dec 5 |
|
Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. | 2013 Nov |
|
The binding of silibinin to ERp57. | 2014 Apr 25 |
|
Silibinin potentially attenuates arsenic-induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. | 2014 Mar |
|
Silibinin induces apoptosis of HT29 colon carcinoma cells through early growth response-1 (EGR-1)-mediated non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) up-regulation. | 2014 Mar 25 |
|
Blockade of lipid accumulation by silibinin in adipocytes and zebrafish. | 2015 Feb 5 |
Sample Use Guides
70 mg or 140 mg capsule should be taken 3 times daily. The medication should be continued until the relief of the symptoms according to the advice of a physician.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17305535
Silybin at pharmacologically achievable in vivo concentrations (0.02–20 uM) increased insulin-like growth factorbinding protein 3 (IGFBP-3) accumulation in androgenindependent prostate cancer PC-3 cells in conditioned medium and caused a dose-dependent increase of IGFBP-3 mRNA abundance with a 9-fold increase over baseline at 20 uM concentration.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:01:35 UTC 2023
by
admin
on
Fri Dec 15 19:01:35 UTC 2023
|
Record UNII |
33X338MNE4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
33X338MNE4
Created by
admin on Fri Dec 15 19:01:36 UTC 2023 , Edited by admin on Fri Dec 15 19:01:36 UTC 2023
|
PRIMARY | |||
|
31553
Created by
admin on Fri Dec 15 19:01:36 UTC 2023 , Edited by admin on Fri Dec 15 19:01:36 UTC 2023
|
PRIMARY | |||
|
DTXSID8026018
Created by
admin on Fri Dec 15 19:01:36 UTC 2023 , Edited by admin on Fri Dec 15 19:01:36 UTC 2023
|
PRIMARY | |||
|
651520
Created by
admin on Fri Dec 15 19:01:36 UTC 2023 , Edited by admin on Fri Dec 15 19:01:36 UTC 2023
|
PRIMARY | |||
|
245-302-5
Created by
admin on Fri Dec 15 19:01:36 UTC 2023 , Edited by admin on Fri Dec 15 19:01:36 UTC 2023
|
PRIMARY | |||
|
22888-70-6
Created by
admin on Fri Dec 15 19:01:36 UTC 2023 , Edited by admin on Fri Dec 15 19:01:36 UTC 2023
|
PRIMARY | |||
|
m9941
Created by
admin on Fri Dec 15 19:01:36 UTC 2023 , Edited by admin on Fri Dec 15 19:01:36 UTC 2023
|
PRIMARY | |||
|
300000005280
Created by
admin on Fri Dec 15 19:01:36 UTC 2023 , Edited by admin on Fri Dec 15 19:01:36 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|